Literature DB >> 2338118

Impairment of estramustine phosphate absorption by concurrent intake of milk and food.

P O Gunnarsson1, T Davidsson, S B Andersson, C Backman, S A Johansson.   

Abstract

The effect of milk and food on the pharmacokinetics of estramustine phosphate was investigated in six patients with prostatic cancer. In a randomized three-way cross-over study, the patients were given single doses of the drug together with low calcium water, low calcium food and milk. The evaluation was based upon the plasma concentration of two metabolites, estromustine and estrone, as parent drug could not be detected in plasma. The tmax and lag time of estromustine were significantly increased by milk and food intake and Cmax and AUC were significantly decreased. In comparison with water, the AUC of estromustine was 41% when the drug was taken with milk and 67% after simultaneous intake of standardized food. Corresponding figures for the peak values were 32 and 57%, respectively. The effect of milk and food intake on the pharmacokinetics of estrone was similar. Studies in vitro demonstrated that the dissolution of estramustine phosphate disodium was markedly impaired in the presence of calcium. It was concluded that the rate and extent of absorption of estramustine phosphate were decreased when the drug was taken with milk or food due to the formation of a poorly absorbable calcium complex. To obtain high and reproducible absorption of Estracyt, the drug should not be taken together with milk, milk products or other calcium-rich food or drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338118     DOI: 10.1007/bf00265983

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Drug interactions in the gut involving metal ions.

Authors:  P F D'Arcy; J C McElnay
Journal:  Rev Drug Metab Drug Interact       Date:  1985

2.  Gas chromatographic determination of four metabolites of estramustine phosphate in plasma.

Authors:  S B Andersson; R Lundgren; L Svensson
Journal:  Acta Pharm Suec       Date:  1982

3.  Radioimmunoassay of estramustine phosphate in plasma.

Authors:  B Forsgren; P O Gunnarsson; S A Johansson; R Kant
Journal:  Acta Pharm Suec       Date:  1978

Review 4.  The effect of food on drug bioavailability.

Authors:  R D Toothaker; P G Welling
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

5.  Influence of milk products on fluoride bioavailability in man.

Authors:  J Ekstrand; M Ehrnebo
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.

Authors:  P O Gunnarsson; S B Andersson; S A Johansson; T Nilsson; G Plym-Forshell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.

Authors:  B J Norlén; S B Andersson; P Björk; P O Gunnarsson; A Fritjofsson
Journal:  J Urol       Date:  1988-11       Impact factor: 7.450

8.  Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3.

Authors:  B Hartley-Asp
Journal:  Prostate       Date:  1984       Impact factor: 4.104

Review 9.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

10.  Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?

Authors:  C R Pinkerton; S G Welshman; J F Glasgow; J M Bridges
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

View more
  8 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 3.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

Review 4.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 5.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

6.  Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

Authors:  E H Hernes; S D Fosså; S Vaage; P Ogreid; A Heilo; E Paus
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  Polypharmacy and Malnutrition Management of Elderly Perioperative Patients with Cancer: A Systematic Review.

Authors:  Eiji Kose; Hidetaka Wakabayashi; Nobuhiro Yasuno
Journal:  Nutrients       Date:  2021-06-07       Impact factor: 5.717

8.  Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.

Authors:  A T Bergenheim; P O Gunnarsson; K Edman; E von Schoultz; M I Hariz; R Henriksson
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.